Skip to main content
. Author manuscript; available in PMC: 2024 Oct 5.
Published in final edited form as: Allergy. 2022 Sep 1;78(1):258–269. doi: 10.1111/all.15481

FIGURE 3.

FIGURE 3

The plasma ratio and uEDN ratio significantly decrease in response to benralizumab and mepolizumab compared to placebo. The EDN ratio was assessed from plasma (**p < 0.01, ****p < 0.0001) and urine (**p < 0.01, ***p < 0.001) collected from (A) PDGFRA-negative HES patients at baseline and week 12 receiving placebo (N = 9), or benralizumab (N = 10), the open symbols represent nonresponders, and (B) EGPA patients at baseline and week 24 receiving placebo (N = 22) or mepolizumab (N = 25)